Hello from #SMFM26! Be sure to check out our symposium, presentations and connect with our team at booth #210! See details below 👇

We recently announced the launch of EDEN, a large, multi-center prospective study designed to evaluate Natera’s NIPT for early risk assessment of preeclampsia and other serious pregnancy complications. Read the full announcement: https://ow.ly/74IH50YccZf

We are proud to collaborate with Exelixis on the planned, phase III pivotal trial (STELLAR-316). It's another example of Natera's "Treat on Molecular Recurrence" approach, where patients will be treated with therapy if they test positive with Signatera™. Learn more: www.natera.com/company/news...

Our expanded 21-gene Fetal Focus™ single-gene non-invasive prenatal test is now available. https://ow.ly/rfUg50XSeWM

Together with Quantum Leap Healthcare Collaborative, we’re excited to share that new findings from the I-SPY 2 trial were published in Nature Communications. This publication shows Signatera™ can predict treatment response and recurrence risk in early-stage breast cancer. https://ow.ly/BYZR50XKpKV

Findings from RenaCARE, evaluating management of CKD one year after RenasightTM testing have been published in @asnpublications.bsky.social. Results show how genetic insights informed diagnosis, prognosis and family care decisions. https://ow.ly/cuze50XFUAH #CKD #Natera #Renasight

Personalized ctDNA testing for MRD is transforming adjuvant therapy decisions in muscle-invasive bladder cancer. Petros Grivas covers ctDNA's perioperative role, key trial data, and much more in this 30-min webinar. Watch now: www.emjreviews.com/en-us/amj/on... This content was funded by Natera.

Attending #SABCS25? Be sure to stop by booth 1309 to meet the Natera team and discuss our latest data. Below is our full list of presentations, showcasing Signatera™ as a leader in MRD testing across early and metastatic breast cancer. Learn more: https://ow.ly/iRP450XGmS5

Thank you to everyone who connected with us at #ASH25. We appreciated the opportunity to discuss emerging data and collaborate with colleagues. Learn more about the value Signatera™ can offer to lymphoma patients for personalized and precise care: www.natera.com/oncology/sig...

Today, Natera announced the acquisition of @foresight-dx.bsky.social. This combination brings together Foresight’s phased variant technology with Natera’s Signatera™ platform to further strengthen performance across both solid tumors and hematologic cancers. www.natera.com/company/news...

We're looking forward to the ASH Annual Meeting this week. View the list of our presentations below and learn more here: https://ow.ly/bbIS50XBvGV #ASH25 #Natera

Kyle’s experience with stage IV colon cancer underscores the role of early detection and personalized care. With the help of Signatera™ MRD testing, Kyle’s care team identified recurrence before imaging could and took swift action. See his full story: https://ow.ly/czIF50XAbPg #MRDtesting #Natera

Across roles and teams at Natera, our genetic counselors help make complex science understandable and personal. They support patients, providers and colleagues alike. Their insights drive innovation and make a difference in every strand of what we do. 🧬 Thank you to our Genetic Counselors! #Natera

Thanks to everyone who attended our presentations and stopped by our booth at #KidneyWk so far. If you haven't yet, we look forward to connecting with you at booth 275! www.natera.com/organ-health/

👋 #KidneyWk, stop by booth 725 to meet our team, discuss genetics and recharge with some coffee! ow.ly/Jsht50Xokx9 #Natera

Anj's family history of breast cancer led her to early mammogram screenings and her diagnosis. Today, she's using Signatera™ with her care team to monitor for recurrence. Watch her full story here: ow.ly/cpfR50Xojqr #Natera

Safe travels to everyone attending #KidneyWk! See you soon at booth 725. www.natera.com/organ-health/ #Natera

Naterans assembled Kynd Kits through Project Helping to benefit @firstdescents.bsky.social, a non-profit that provides life-changing outdoor adventures for young adults impacted by cancer and other serious health conditions. 💙💚 #TeamNatera #Natera

See you soon for #KidneyWk! Stop by booth # 725 to speak to our team. See below for details on the ways we're supporting genetics in the field of nephrology. @asnkidney.bsky.social #Natera

Join us at #NSGC25 for our presentations, events and highly anticipated resume review! Learn more in the flyer below and be sure to stop by booth #517 to speak with our team. #Natera #GeneticCounselors #GeneticCounseling #GC

New data from our PROCEED-CRC trial showed 22.5% sensitivity and 91.5% specificity for detecting advanced adenomas — precancerous polyps linked to the development of colorectal cancer. These results mark continued progress in our early cancer detection program. www.natera.com/company/news...

Proud to support the 4th Annual Gathering of the Wolves, hosted by Man Up To Cancer, an organization dedicated to supporting men with any kind of cancer diagnosis, providing community and resources to guide them through treatment and beyond. #Natera #ManUpToCancer Man Up to Cancer#Natera

Natera is honored to be a national sponsor of the Susan G. Komen More Than Pink Walk series. Together, we walk for hope, progress and a future without breast cancer. Thank you, Susan G. Komen, for welcoming us into this incredible community. 💗 #MoreThanPink #Natera Susan G. Komen#MoreThanPink

Natera has been named to @fastcompany.com’s 2025 Next Big Things in Tech list for Signatera™, our personalized MRD test that’s redefining how cancer is detected and managed. ow.ly/wFg050XblTy #FCTechAwards #Natera

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results: nej.md/3WIRtEg #ESMO25

We’re pleased to share a pivotal moment in MRD testing for Signatera™, with the New England Journal of Medicine publishing the results of IMvigor011. www.nejm.org/doi/full/10.... #ESMO25 #Natera

Natera’s technology will be featured across multiple presentations at #ESMO2025. See the full schedule below and stop by booth #1016 to learn more. #Natera #MRD #Signatera @myesmo.bsky.social

Natera’s technology will be featured in 14 studies at the ESMO - European Society for Medical Oncology Congress, including 6 oral presentations. We look forward to connecting at #ESMO25 as we continue advancing personalized, MRD-guided cancer care for patients everywhere. https://ow.ly/XJ1x50XaKc1

We're honored to support the Bottoms Up Invitational by Colorectal Cancer Alliance. This event helps increase awareness for screening, fund research and support those affected by #ColorectalCancer. Learn more at: https://ow.ly/bOio50X3ZkJ#ColorectalCancerPhoto credit: Andrew H. Walker/Shutterstock

Join us as we celebrate survivors, thrivers & their families at the #SusanGKomen More Than Pink Walk series! #Natera is grateful and honored to be a part of the community. 💗 Miami, FL - 10/4 💗 San Francisco, CA - 10/5 💗 Oxand Hill, MD - 10/11 💗 Austin, TX - 10/26 💗 Los Angeles, CA -10/26

Hello #NPWH2025 attendees!👋 Our team is thrilled to welcome you to booth #318 and share the latest innovations in maternal health and genetic testing. #Natera #NPWH @npwh.bsky.social

Andrea ‘Anj’ Oto knew that she had an increased risk of developing cancer due to her family history. Anj went in for her annual mammogram and her care team saw something suspicious that led to further testing — and a #breastcancer diagnosis. #Natera Watch her story: https://ow.ly/XmZv50X4vhG

"Signatera gives me the power to go on with my life instead of constantly wondering ‘what-if.’" Two days after a visit to the emergency room, Holly underwent surgery and received a rare ovarian cancer diagnosis. www.natera.com/resource-lib... #OvarianCancerAwareness #Signatera #MRDtesting #Natera

Join our upcoming webinar w/ Katie Hashimoto, MS, CGC, Chris Sullivan, MD, FACOG & Dr. Shailen Shah, MD. Review the latest advancements and unique capabilities of SNP-based NIPT and explore real-world case studies. Register today: ow.ly/u9B650WX48I

Today is #TealDay for ovarian cancer awareness and Team #Natera dressed in teal to show their support! Our partner is National Ovarian Cancer Coalition, an incredible resource for statistics, support, and more to empower your healthcare journey. 💙💚 Learn more: ow.ly/ASPU50WSaIL

Join this upcoming webinar with Dr. Midhun Malla and @dougfloramd.bsky.social as they discuss the role of #ctDNA testing for MRD assessment in #GICancer management. 🗓️ Sept 10 | 4 PM ET Register today: ow.ly/nm3150WN6y5 #Natera

Why test for genetic causes of kidney disease? Genetic testing can reveal answers that may change the course of care for patients and their families. Learn more about Renasight: ow.ly/gnm750WvvAj #Natera #Renasight #KidneyHealth

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit Read the full announcement here: www.natera.com/company/news...

Did you know that it's common to be a carrier of a genetic condition, even w/out any noticeable symptoms or family history?🧬 🤰 Horizon Carrier Screening is a genetic test that can be done before or during pregnancy. Learn more: ow.ly/qp7T50WfIU5 #Natera

Thank you for an incredible #WTC2025 & to our #Natera team for the success of: 🔬 16 abstracts in kidney, heart & lung 📊 The latest data on Prospera 🎤 Standing room only at our symposium with leading voices in transplant medicine @astsconnect.bsky.social @astinfo.bsky.social @ttsorg.bsky.social

Hello from #WTC2025 in SF👋Thank you to those who attended our exclusive lab tour! Stop by booth #1002 to learn more about the technology behind #Prospera and connect w/ our team. RSVP here for our events ➡️ ow.ly/KoUj50Wz887 #Natera @astsconnect.bsky.social @ttsorg.bsky.social @astinfo.bsky.social

See you soon at #WTC2025! We will have 16 abstracts spanning our organ health offerings in kidney, heart & lung including 5 oral presentations, showcasing several high-impact datasets. Read more about our presentations here: ow.ly/cx1v50WyIwx

Adanma Ayanambakkam, MD, genitourinary oncologist at Stephenson Cancer Center shares recent data on the prognostic value of ctDNA-based MRD detection in patients with upper tract urothelial cancer. #MRDTesting #Natera #Signatera Watch the video: www.natera.com/resource-lib...

💙💚 This #WorldIVFDay & #WorldEmbryologistDay we celebrate the experts who help families grow. Thank you for your work and the crucial role you play in shaping the future of reproductive health. ow.ly/zqU050WuXhv #Natera

We look forward to connecting at #WTC2025 in San Francisco, August 2 - 6. Join us for special events highlighting the latest in transplant innovation, including a tour of our local #Natera lab. RSVP: ow.ly/AKMq50WsQkq @ttsorg.bsky.social @astinfo.bsky.social @astsconnect.bsky.social

Here is part 2 of our podcast from the UK Oncology Forum, about a potentially life-saving pilot project between the alliance and Natera. Listen now! Spotify: bit.ly/4kIaelI Apple: bit.ly/443sfUm Amazon: bit.ly/4jYkzc9 YouTube: bit.ly/43M6LNd

We’re excited to present at #ESMOGI25. These presentations highlight the continued clinical value of Signatera for molecular residual disease (MRD) assessment across colorectal and rectal cancers, including new clinical validation data on our tissue-free MRD assay. www.natera.com/company/news...

🌎 Natera’s 2024 Sustainability Report is now live! This report reflects the efforts of teams across #Natera to help reduce environmental impact, support our communities and foster a culture of belonging, while expanding access to our technology for more patients than ever before. ow.ly/xuRB50Wg4sH

Happy Father’s Day to every kind of dad—by birth, by choice, or by example. Your guidance, support, and love make a lasting difference. 💙 #FathersDay #Gratitude #Fatherhood

We're pleased to be at the Midwest Reproductive Symposium International 2025 Annual Meeting this week! Stop by booth # 56 and come chat with our team to learn more about genetic tests in reproductive health. #MRSi2025 #IVF #Natera